- 數據解釋
| Last Price | 成交價 | Last Trade | 最後交易日 |
|---|---|---|---|
| Tick | 比前一筆成交價之漲跌 | Volume | 交易量 |
| Change | 漲跌 | % Change | 漲跌幅 |
| Open | 開盤價 | Prev Close | 前日收盤價 |
| Day High | 當天最高價 | Day Low | 當天最低價 |
| Bid | 買入價 | Bid Size | 委買量、買單大小 |
| Ask | 賣出價 | Ask Size | 賣量、賣單大小 |
| 52Wk High | 52周最高價 | 52Wk Low | 52周最低價 |
| E.P.S. | 每股收益、每股盈餘 | P/E Ratio | 本益比、市盈率 |
| Ex-Div Date | 除息日 | Dividend | 股利 |
| Yield | 殖利率、收益率 | Shares | 流通股數 |
| Market Cap | 市值 | Exchange | 交易所 |
| NYE (New York Stock Exchange) | 紐約證券交易所 |
|---|---|
| AMX (American Stock Exchange) | 美國證券交易所 |
| NGS (Nasdaq Global Select) | 納斯達克全球精選市場 |
| NGM (NASDAQ Global Market) | 納斯達克全球市場 |
| NSC (Nasdaq Small Caps) | 納斯達克資本市場 |
| OTO (Other-OTC) | 場外交易市場 |
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
2024-11-20
2024-11-20
2024-11-20
| 排名 | 股票名稱 | 持有比例% |
|---|---|---|
| 1 | Seattle Genetics Inc. | 4.7% |
| 2 | Anacor Pharmaceuticals Inc. | 4.5% |
| 3 | Neurocrine Biosciences Inc. | 4.4% |
| 4 | ACADIA Pharmaceuticals Inc. | 4.05% |
| 5 | Intercept Pharmaceuticals Inc. | 3.87% |